Advertisement

Relation Between Paradoxical Decrease in High-Density Lipoprotein Cholesterol Levels After Statin Therapy and Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction

Published:December 16, 2014DOI:https://doi.org/10.1016/j.amjcard.2014.11.043
      Statin therapy moderately increases high-density lipoprotein cholesterol (HDL-C) levels. Contrary to this expectation, a paradoxical decrease in HDL-C levels after statin therapy is seen in some patients. We evaluated 724 patients who newly started treatment with statins after acute myocardial infarction (AMI). These patients were divided into 2 groups according to change in HDL-C levels between baseline and 6 to 9 months after initial AMI (ΔHDL). In total, 620 patients had increased HDL-C levels and 104 patients had decreased HDL-C levels. Both groups achieved follow-up low-density lipoprotein cholesterol levels <100 mg/dl. Adverse cardiovascular events (a composite of all-cause death, myocardial infarction, and stroke) have more frequently occurred in the decreased HDL group compared with the increased HDL group (15.4% vs 7.1%, p = 0.01). Multivariate analysis showed that decreased HDL, onset to balloon time, and multivessel disease were the independent predictors of adverse cardiovascular events (hazard ratio [HR] 1.95, 95% confidence interval [CI] 1.08 to 3.52; HR 1.05, 95% CI 1.01 to 1.09; and HR 2.08, 95% CI 1.22 to 3.56, respectively). In conclusion, a paradoxical decrease in serum HDL-C levels after statin therapy might be an independent predictor of long-term adverse cardiovascular events in patients with AMI.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wilson P.W.
        • Garrison R.J.
        • Castelli W.P.
        • Feinleib M.
        • McNamara P.M.
        • Kannel W.B.
        Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols.
        Am J Cardiol. 1980; 46: 649-654
        • Di Angelantonio E.
        • Sarwar N.
        • Perry P.
        • Kaptoge S.
        • Ray K.K.
        • Thompson A.
        • Wood A.M.
        • Lewington S.
        • Sattar N.
        • Packard C.J.
        • Collins R.
        • Thompson S.G.
        • Danesh J.
        • Emerging Risk Factors Collaboration
        Major lipids, apolipoproteins, and risk of vascular disease.
        JAMA. 2009; 302: 1993-2000
        • Gordon D.J.
        • Probstfield J.L.
        • Garrison R.J.
        • Neaton J.D.
        • Castelli W.P.
        • Knoke J.D.
        • Jacobs Jr., D.R.
        • Bangdiwala S.
        • Tyroler H.A.
        High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
        Circulation. 1989; 79: 8-15
        • Wilson P.W.
        • Abbott R.D.
        • Castelli W.P.
        High density lipoprotein cholesterol and mortality. The Framingham Heart Study.
        Arteriosclerosis. 1988; 8: 737-741
        • Fruchart J.C.
        • Sacks F.
        • Hermans M.P.
        • Assmann G.
        • Brown W.V.
        • Ceska R.
        • Chapman M.J.
        • Dodson P.M.
        • Fioretto P.
        • Ginsberg H.N.
        • Kadowaki T.
        • Lablanche J.M.
        • Marx N.
        • Plutzky J.
        • Reiner Z.
        • Rosenson R.S.
        • Staels B.
        • Stock J.K.
        • Sy R.
        • Wanner C.
        • Zambon A.
        • Zimmet P.
        The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
        Am J Cardiol. 2008; 102: 1K-34K
        • Barter P.
        • Gotto A.M.
        • LaRosa J.C.
        • Maroni J.
        • Szarek M.
        • Grundy S.M.
        • Kastelein J.J.
        • Bittner V.
        • Fruchart J.C.
        • Treating to New Targets Investigators
        HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular event.
        N Engl J Med. 2007; 357: 1301-1310
        • Nicholls S.J.
        • Tuzcu E.M.
        • Sipahi I.
        • Grasso A.W.
        • Schoenhagen P.
        • Hu T.
        • Wolski K.
        • Crowe T.
        • Desai M.Y.
        • Hazen S.L.
        • Kapadia S.R.
        • Nissen S.E.
        Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
        JAMA. 2007; 297: 499-508
        • Hayashi Y.
        • Okumura K.
        • Matsui H.
        • Imamura A.
        • Miura M.
        • Takahashi R.
        • Murakami R.
        • Ogawa Y.
        • Numaguchi Y.
        • Murohara T.
        Impact of low-density lipoprotein particle size on carotid intima-media thickness in patients with type 2 diabetes mellitus.
        Metabolism. 2007; 56: 608-613
        • Matsudaira K.
        • Maeda K.
        • Okumura N.
        • Yoshikawa D.
        • Morita Y.
        • Mitsuhashi H.
        • Ishii H.
        • Kondo T.
        • Murohara T.
        The impact of low vascular endothelial growth factor levels after myocardial infarction on the 6-month clinical outcome: results from the Nagoya Acute Myocardial Infarction Study.
        Circ J. 2012; 76: 1509-1516
        • Suzuki S.
        • Ishii H.
        • Matsudaira K.
        • Okumura N.
        • Yoshikawa D.
        • Hayashi M.
        • Maeda K.
        • Kondo T.
        • Kondo T.
        • Ichimiya S.
        • Kato R.
        • Matsubara T.
        • Murohara T.
        Long-term outcome of drug-eluting versus bare-metal stents in patients with acute myocardial infarction—subgroup analysis of the Nagoya Acute Myocardial Infarction Study (NAMIS).
        Circ J. 2013; 77: 2024-2031
        • Morita Y.
        • Maeda K.
        • Kondo T.
        • Ishii H.
        • Matsudaira K.
        • Okumura N.
        • Mitsuhashi H.
        • Shibata R.
        • Murohara T.
        The impact of adiponectin and leptin on long-term adverse events in Japanese patients with acute myocardial infarction: results from the Nagoya Acute Myocardial Infarction Study (NAMIS).
        Circ J. 2013; 77: 2778-2785
        • Matsuo S.
        • Imai E.
        • Horio M.
        • Yasuda Y.
        • Tomita K.
        • Nitta K.
        • Yamagata K.
        • Tomino Y.
        • Yokoyama H.
        • Hishida A.
        • Collaborators developing the Japanese equation for estimated GFR
        Revised equations for estimated GFR from serum creatinine in Japan.
        Am J Kidney Dis. 2009; 53: 982-992
        • Okamura T.
        • Hayakawa T.
        • Kadowaki T.
        • Kita Y.
        • Okayama A.
        • Ueshima H.
        • NIPPON DATA90 Research Group
        The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population.
        Atherosclerosis. 2006; 184: 143-150
        • Grover S.A.
        • Kaouache M.
        • Joseph L.
        • Barter P.
        • Davignon J.
        Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
        Arch Intern Med. 2009; 169: 1775-1780
        • Dean B.B.
        • Borenstein J.E.
        • Henning J.M.
        • Knight K.
        • Merz C.N.
        Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?.
        Am Heart J. 2004; 147: 966-976
        • Seo S.M.
        • Choo E.H.
        • Koh Y.S.
        • Park M.W.
        • Shin D.I.
        • Choi Y.S.
        • Park H.J.
        • Kim D.B.
        • Her S.H.
        • Lee J.M.
        • Park C.S.
        • Kim P.J.
        • Moon K.W.
        • Chang K.
        • Kim H.Y.
        • Yoo K.D.
        • Jeon D.S.
        • Chung W.S.
        • Park Y.G.
        • Seung K.B.
        • Catholic University of Korea
        • Percutaneous Coronary Intervention Registry Investigators
        High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention.
        Heart. 2011; 97: 1943-1950
        • White H.D.
        • Simes R.J.
        • Anderson N.E.
        • Hankey G.J.
        • Watson J.D.
        • Hunt D.
        • Colquhoun D.M.
        • Glasziou P.
        • MacMahon S.
        • Kirby A.C.
        • West M.J.
        • Tonkin A.M.
        Pravastatin therapy and the risk of stroke.
        N Engl J Med. 2000; 343: 317-326
        • Barter P.J.
        • Brandrup-Wognsen G.
        • Palmer M.K.
        • Nicholls S.J.
        Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.
        J Lipid Res. 2010; 51: 1546-1553
        • Martin G.
        • Duez H.
        • Blanquart C.
        • Berezowski V.
        • Poulain P.
        • Fruchart J.C.
        • Najib-Fruchart J.
        • Glineur C.
        • Staels B.
        Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
        J Clin Invest. 2001; 107: 1423-1432
        • Bays H.
        • Stein E.A.
        Pharmacotherapy for dyslipidaemia—current therapies and future agents.
        Expert Opin Pharmacother. 2003; 4: 1901-1938
        • Assmann G.
        • Schulte H.
        • von Eckardstein A.
        • Huang Y.
        High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport.
        Atherosclerosis. 1996; 124: S11-S20
        • Brewer Jr., H.B.
        Increasing HDL cholesterol levels.
        N Engl J Med. 2004; 350: 1491-1494
        • Bots M.L.
        • Visseren F.L.
        • Evans G.W.
        • Riley W.A.
        • Revkin J.H.
        • Tegeler C.H.
        • Shear C.L.
        • Duggan W.T.
        • Vicari R.M.
        • Grobbee D.E.
        • Kastelein J.J.
        RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
        Lancet. 2007; 370: 153-160
        • Navab M.
        • Anantharamaiah G.M.
        • Reddy S.T.
        • Van Lenten B.J.
        • Ansell B.J.
        • Fogelman A.M.
        Mechanisms of disease: proatherogenic HDL—an evolving field.
        Nat Clin Pract Endocrinol Metab. 2006; 2: 504-511
        • Ansell B.J.
        • Watson K.E.
        • Fogelman A.M.
        • Navab M.
        • Fonarow G.C.
        High-density lipoprotein function recent advances.
        J Am Coll Cardiol. 2005; 46: 1792-1798
        • Amarenco P.
        • Bogousslavsky J.
        • Callahan III, A.
        • Goldstein L.B.
        • Hennerici M.
        • Rudolph A.E.
        • Sillesen H.
        • Simunovic L.
        • Szarek M.
        • Welch K.M.
        • Zivin J.A.
        • Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
        High-dose atorvastatin after stroke or transient ischemic attack.
        N Engl J Med. 2006; 355: 549-559
        • Amarenco P.
        • Labreuche J.
        • Touboul P.J.
        High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review.
        Atherosclerosis. 2008; 196: 489-496
        • Tirschwell D.L.
        • Smith N.L.
        • Heckbert S.R.
        • Lemaitre R.N.
        • Longstreth Jr., W.T.
        • Psaty B.M.
        Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups.
        Neurology. 2004; 63: 1868-1875
        • Tahara N.
        • Kai H.
        • Ishibashi M.
        • Nakaura H.
        • Kaida H.
        • Baba K.
        • Hayabuchi N.
        • Imaizumi T.
        Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography.
        J Am Coll Cardiol. 2006; 48: 1825-1831